What is it about?
The research investigates the CD64/CD28/CD3ζ chimeric receptor's effects on T-cell metabolism, persistence, and immune functions in colorectal cancer and head and neck squamous cell carcinoma. CD64/CD28/CD3ζ T cells significantly impact the rational design of personalized studies to treat colorectal cancer and head and neck squamous cell carcinoma and the identification of novel FcγR alternative ligands in cancer and healthy cells.
Featured Image
Photo by National Institute of Allergy and Infectious Diseases on Unsplash
Read the Original
This page is a summary of: The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity, Experimental Hematology and Oncology, February 2025, Springer Science + Business Media,
DOI: 10.1186/s40164-025-00601-2.
You can read the full text:
Resources
Contributors
The following have contributed to this page
